FDA approves first Botulism Antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes

The U.S. Food and Drug Administration announced today that it has approved Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) to treat patients showing signs of botulism following documented or suspected exposure to botulinum neurotoxin. The product is derived from horse plasma and contains a mixture of antibody fragments that neutralize all of the seven botulinum nerve toxin serotypes known to cause botulism.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm

Source: Food and Drug Administration - March 22, 2013 Category: American Health Source Type: news

More News: American Health | Botulism | Food and Drug Administration (FDA) | Neurology